Pembrolizumab has been the default first-line standard for PD-L1-positive non-small cell lung cancer for nearly a decade, which makes the HARMONi-2 overall survival result genuinely difficult to set aside. Ivonescimab monotherapy beat pembrolizumab monotherapy on overall survival in a pre-specified interim analysis of the randomized, double-blind Phase 3 trial, with Akeso announcing the result statistically significant and clinically meaningful. The 8-K Summit Therapeutics filed September 2, 2026 relays that finding under “Other Events,” which is how a U.S. partner surfaces a foreign partner’s data to investors without a separate press conference.
The design matters here. HARMONi-2 compared ivonescimab against pembrolizumab as monotherapy in patients with locally advanced or metastatic NSCLC whose tumors are PD-L1 positive, which is the exact population pembrolizumab has dominated as a single agent. Ivonescimab is a PD-1/VEGF bispecific antibody, simultaneously blocking the checkpoint pathway and VEGF-driven angiogenesis, which is the biological rationale for why it might outperform a PD-1 inhibitor alone. An OS win on that head-to-head comparison, rather than on PFS alone, removes the most common objection regulators and payers raise when newer combinations show only delayed progression.
Summit’s stake in this readout traces to a December 2022 license agreement with Akeso, under which Summit paid $500 million upfront for rights to ivonescimab outside China and Australia. The HARMONi-2 data were generated in China under Akeso’s program, so they inform Summit’s regulatory path in the U.S. and Europe but do not constitute a submission-ready package on their own. Summit is running its own global ivonescimab trials, and how the FDA weighs a China-conducted OS readout when evaluating a U.S. application will be the regulatory question that shapes the program’s timeline from here.
Specific OS numbers, including median survival and hazard ratio, were not disclosed in this filing, which means the full dataset presentation at a medical meeting is the next concrete event to watch. The magnitude of the survival separation will determine whether this result translates into a commercially and regulatorily decisive story outside China.
Source link: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000076/smmt-20260902.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
